GlassScriptPhysician profile
Mark T Mahoney
NPI 1689863615
$4,780.26
in general payments reported to CMS, 2019-2025
46 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $805 · 2021: $586 · 2022: $1,041 · 2023: $875 · 2024: $351 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $753.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $453.75 | 2019-2024 | Mounjaro |
| Abbvie INC. | $443.04 | 2020-2025 | |
| Glaxosmithkline, LLC. | $350.36 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $257.49 | 2021-2025 | |
| Abbott Laboratories | $246.48 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $205.64 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $175.88 | 2019-2025 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $168.96 | 2019-2021 | |
| Baxter Healthcare | $155.57 | 2022 | |
| Allergan, INC. | $151.92 | 2020 | |
| Janssen Pharmaceuticals, INC | $150.30 | 2019-2023 | Spravato |
| Lundbeck LLC | $141.54 | 2022-2024 | Vyepti |
| Amgen INC. | $123.24 | 2021-2023 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $108.33 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mahoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.